NCT04061746View on ClinicalTrials.gov

Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 27, 2020

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions
Diabetes Mellitus, Type 1
Interventions
BIOLOGICAL

Mesenchymal Stem Cells (MSCs)

Patients in Group A will receive a single MSCs infusion

OTHER

Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)

Patients in Group B will receive a single infusion of placebo (Plasmalyte A with 0.5% human serum albumin)

Trial Locations (1)

29425

RECRUITING

Medical University of South Carolina, Charleston

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Medical University of South Carolina

OTHER